Immunic Appoints Michael W. Bonney as Chair of the Board

Immunic, a late-stage biotech firm focused on novel oral therapies for neurologic diseases, has appointed Michael W. Bonney as Chair of its Board of Directors. Bonney, a seasoned executive with over 30 years in the biopharmaceutical industry, assumed this role on May 16, 2026. He has significant experience in the multiple sclerosis (MS) market, notably contributing to the success of Avonex® during his tenure at Biogen Inc.

Bonney also served as CEO of Cubist Pharmaceuticals, overseeing its growth and eventual acquisition by Merck & Co. He currently holds several board positions across the biopharmaceutical sector. His appointment comes as Immunic advances its lead program, vidofludimus calcium, towards regulatory approval for relapsing MS.